MLSS

Business Context and Reporting Period

Company: Milestone Scientific Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2010
Business Overview: Milestone Scientific develops and markets computer-controlled local anesthesia delivery (C-CLAD) systems, primarily the STA Single Tooth Anesthesia System® and CompuDent®/The Wand® instruments. The company is a smaller reporting company focused on expanding its global distribution network, particularly in China, while transitioning its domestic sales model to utilize dental hygienists for education and support.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Nine-month revenue increased 25% to $7.71 million, driven entirely by international shipments, specifically a 107% increase in international revenue due to a large order from a Chinese distributor (Sinopharm). Domestic revenue decreased 18% due to a strategic reduction in the sales force and advertising.
• Profitability Improvement: The net loss for the nine months ended September 30, 2010, improved significantly to $319,244 compared to $1.59 million in the prior year period. Gross margin expanded to 64% from 60% due to reduced manufacturing costs for the STA system.
• Expense Management: Selling, general, and administrative (SG&A) expenses remained relatively flat year-over-year ($5.02M vs $4.96M) despite revenue growth, due to significant reductions in marketing and consulting expenses offset by higher international commissions and royalties.
• Liquidity Position: Cash and cash equivalents declined from $1.03 million at year-end 2009 to $207,726 at September 30, 2010. This decrease was primarily due to increased advances to contract manufacturers ($1.73M) and inventory buildup to fulfill the China order.

Guidance, Outlook, and Risks

• Strategic Shift: Management is transitioning the domestic business model from a traditional sales force to a team of local dental hygienists for training and education. International expansion remains a primary growth driver.
• Capital Needs: The company anticipates requiring additional capital to support higher marketing levels and sales expansion. There is no assurance that capital can be raised on satisfactory terms.
• Going Concern: The filing explicitly states that historical losses raise substantial doubt about the company's ability to continue as a going concern. If positive cash flow is not achieved or capital cannot be raised, the company may be forced to curtail development or reduce marketing.
• Concentration Risk: Three customers accounted for 63% of revenue for the nine months ended September 30, 2010. One major customer (Sinopharm in China) accounted for 24% of revenue. Accounts receivable from these three customers represented 77% of total gross receivables.
• Manufacturing Dependence: The company relies on contract manufacturers (e.g., Tricor Systems, Inc.) for production. Termination of these relationships could materially adversely affect operations.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the remaining $207,726 in cash against the projected burn rate and the timeline for the China order delivery to ensure solvency.
• China Order Execution: Confirm the status of the 12,000-unit purchase order with Sinopharm, including delivery schedules and the timing of revenue recognition versus cash collection.
• Receivables Quality: Assess the collectability of the $1.58 million in receivables owed by the top three customers, given the high concentration risk.
• Debt Obligations: Review the terms of the $450,000 shareholder note (due June 30, 2012) and the accrued interest of approximately $220,000 to understand upcoming liquidity pressures.
• Domestic Sales Transition: Monitor the effectiveness of the new hygienist-based sales model in reversing the 18% decline in domestic revenue.